Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) insider Greg Madison sold 4,055 shares of the company’s stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $6.03, for a total value of $24,451.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Greg Madison also recently made the following trade(s):
- On Thursday, October 5th, Greg Madison sold 895 shares of Keryx Biopharmaceuticals stock. The stock was sold at an average price of $7.19, for a total value of $6,435.05.
Shares of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) opened at 6.48 on Wednesday. Keryx Biopharmaceuticals, Inc. has a 52-week low of $4.11 and a 52-week high of $8.38. The stock’s market capitalization is $769.50 million. The stock has a 50 day moving average price of $6.87 and a 200-day moving average price of $6.79.
Large investors have recently made changes to their positions in the stock. Fox Run Management L.L.C. bought a new stake in shares of Keryx Biopharmaceuticals during the 3rd quarter valued at about $101,000. Principal Financial Group Inc. grew its position in Keryx Biopharmaceuticals by 4.2% in the 2nd quarter. Principal Financial Group Inc. now owns 14,759 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 590 shares during the last quarter. Raymond James Financial Services Advisors Inc. grew its position in Keryx Biopharmaceuticals by 51.8% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 16,495 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 5,628 shares during the last quarter. Jane Street Group LLC bought a new position in Keryx Biopharmaceuticals in the 1st quarter worth about $141,000. Finally, Legal & General Group Plc grew its position in Keryx Biopharmaceuticals by 1.2% in the 1st quarter. Legal & General Group Plc now owns 25,985 shares of the biopharmaceutical company’s stock worth $161,000 after purchasing an additional 300 shares during the last quarter. 65.20% of the stock is owned by institutional investors and hedge funds.
KERX has been the subject of a number of analyst reports. Zacks Investment Research raised Keryx Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 price target for the company in a report on Wednesday, July 12th. BidaskClub cut Keryx Biopharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Maxim Group reaffirmed a “buy” rating and issued a $9.00 price target on shares of Keryx Biopharmaceuticals in a report on Thursday, July 20th. Cowen and Company reaffirmed a “market perform” rating on shares of Keryx Biopharmaceuticals in a report on Tuesday, July 25th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $7.00 price target (up previously from $4.00) on shares of Keryx Biopharmaceuticals in a report on Tuesday, July 25th. One analyst has rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $7.48.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
What are top analysts saying about Keryx Biopharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Keryx Biopharmaceuticals Inc. and related companies.